Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

Overview of attention for article published in PLOS ONE, April 2012

Altmetric Badge

Mentioned by

news: 1 news outlet
twitter: 3 X users

patent: 3 patents
f1000: 1 research highlight platform

Citations

dimensions_citation: 164 Dimensions

Readers on

mendeley: 128 Mendeley

Summary News X Patents Research highlights Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 656 followers.

RT @bioboybull: $gnpx

Reply Repost Favourite

$gnpx

Reply Repost Favourite

Reqorsa (TUSC2 gene therapy) is a new class of drugs that delivers a tumor suppressor gene to cancers missing that gene - a previously undruggable target. 2/3 #ScienceTwitter #MedTwitter #LungCancer https://t.co/b0aa9KlXKU

Reply Repost Favourite